About 20,000 American women are diagnosed with ovarian cancer each year. Meet some of the biotech innovators working to develop new medicines to better treat—and even cure—this disease.

The US system of private, market-based pricing is the foundation of America’s global leadership in biomedical innovation. Proposals to import government price controls from wealthy foreign trade competitors ignore the extraordinary value that the US pricing system delivers to patients, employers, taxpayers, and health plans.

When measuring the value of new medicines, some countries rely on an outdated and incomplete methodology that understates the true value of innovative treatments. Setting prices in the U.S. based on these artificially low estimates of value would reduce investment in biomedical R&D and yield fewer novel medicines that address critical unmet needs of patients.

Over 3 million Americans are diagnosed with skin cancer each year. Meet some of the biotech innovators working to develop new medicines to better treat—and even cure—this disease.

Nearly a million Americans are living with multiple sclerosis. Meet some of the biotech innovators working to develop new medicines to restore health and happiness to these patients and their families.

Nearly 1 million Americans and over 7 million people globally are living with Parkinson's disease. Meet some of the biotech innovators working to develop new medicines to restore health and happiness to these patients and their families.

The methods many countries use to evaluate new medicines significantly underestimate the true societal benefits of innovative treatments. When high-income countries use traditional methods as a bargaining tool to deny coverage and/or secure lower prices, they free ride on the R&D investments of others and reduce patient access to novel medicines in their own countries.

The Massachusetts biotech industry leads the world in innovation and drug development. But its companies don’t have the support of its own leaders. Why?

US biomedical innovators, the investors that support them, and the patients who depend on continued medical progress rely on the US Food and Drug Administration’s guidance and rigor to navigate policy and medical standards and to approve new medicines. The agency’s reorganization must preserve the institutional knowledge and core functionality that makes the FDA the world’s leading regulatory body.

Beneficiaries say Inflation Reduction Act will worsen access, affordability challenges.

When other countries pay less for drugs, they are free-riding on American innovation and our willingness to pay for new treatments. Forcing manufacturers to charge the same price that these other countries do would backfire. Instead, policymakers should use trade negotiations to pressure other wealthy countries to pay their fair share. No Patient Left Behind wrote to the Office of the United States Trade urging an end to unfair trade practices in drug pricing.

Biomedical innovators are developing new autoimmune therapeutics - insurance reform will ensure new treatments and cures are accessible and affordable.

An independent and autonomous FDA is a key part of ensuring that the biotech innovation ecosystem can continue to thrive. As an agency, it is the gold standard globally for determining risk-reward benefit in therapies for patients, and the world looks to it to lead the way. The people at the FDA are trying hard to make sure that we actually make progress, and their work is a service to the American public.

No Patient Left Behind wrote to the Office of the United States Trade Representative regarding the 2025 Special 301 Review, urging the agency to use its tariff and market access tools to force OECD countries to pay their fair share for medical innovation and end the free-riding of American biomedical innovation.

America is the global leader in biomedical innovation because it has a market that values new medicines. When other countries pay less, they are free-riding on our willingness to pay for new treatments. Forcing drug manufacturers to charge the same price that these other countries mandate would backfire. Instead, policymakers should use trade negotiations to pressure other wealthy countries to pay their fair share.

A new survey demonstrates that a majority of consumers want health plans to lower out-of- pocket costs, but are concerned state government price controls will harm access and not reduce costs

The independence and autonomy of the Food and Drug Administration (FDA) is a key part of ensuring that the biotech innovation ecosystem can continue to thrive. As an agency, it is the gold standard globally for determining risk-reward benefit in therapies for patients, and the world looks to it to lead the way. The people at the FDA facilitate the medical progress we all enjoy, and their work is a service to the American public.